ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Tuberous Sclerosis Complex (TSC)
Gene/Gene Panel: TSC1, TSC2
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2023/02/21
Released
1.1.4
A
Morbidity and mortality from TSC-related lesions (GroupA)
Evaluation by specialist with imaging to guide possible use of mTORi therapy (GroupA) 9CB
Internal system migration to correct the RELEASE VERSION NUMBER.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TSC1 ⇔ 0001734 TUBEROUS SCLEROSIS 1; TSC1
Moderate Actionability
Moderate Actionability
TSC2 ⇔ 0001734 TUBEROUS SCLEROSIS 2; TSC2
Moderate Actionability
Moderate Actionability
2023/02/21
Released (Under revision)
..NaN
A
Morbidity and mortality from TSC-related lesions (GroupA)
Evaluation by specialist with imaging to guide possible use of mTORi therapy (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TSC1 ⇔ 0001734 TUBEROUS SCLEROSIS 1; TSC1
Moderate Actionability
Moderate Actionability
TSC2 ⇔ 0001734 TUBEROUS SCLEROSIS 2; TSC2
Moderate Actionability
Moderate Actionability
2022/10/20
Released
..NaN
A
Morbidity and mortality from TSC-related lesions (GroupA)
Evaluation by specialist with imaging to guide possible use of mTORi therapy (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TSC1 ⇔ 0001734 TUBEROUS SCLEROSIS 1; TSC1
Moderate Actionability
Moderate Actionability
TSC2 ⇔ 0001734 TUBEROUS SCLEROSIS 2; TSC2
Moderate Actionability
Moderate Actionability
2022/10/20
Released (Under revision)
A
Morbidity and mortality from TSC-related lesions (GroupA)
Evaluation by specialist with imaging to guide possible use of mTORi therapy (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TSC1 ⇔ 0001734 TUBEROUS SCLEROSIS 1; TSC1
Moderate Actionability
Moderate Actionability
TSC2 ⇔ 0001734 TUBEROUS SCLEROSIS 2; TSC2
Moderate Actionability
Moderate Actionability
2022/06/02
Released
A
Morbidity and mortality from TSC-related lesions (GroupA)
Evaluation by specialist with imaging to guide possible use of mTORi therapy (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TSC1 ⇔ 0001734 TUBEROUS SCLEROSIS 1; TSC1
Moderate Actionability
Moderate Actionability
TSC2 ⇔ 0001734 TUBEROUS SCLEROSIS 2; TSC2
Moderate Actionability
Moderate Actionability
2022/04/21
Released (Under revision)
1.1.3
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Internal system migration associated with MONDO name addition.
2022/02/09
Released
1.1.3
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Internal system migration associated with MONDO name addition.
2022/02/09
Released (Under revision)
1.1.2
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Edited MONDO ID
2020/04/29
Released
1.1.2
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Edited MONDO ID
2020/04/29
Released (Under revision)
1.1.1
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
added MONDO IDs and created scoring groups
2020/04/16
Released
1.1.1
A
LAM development in women (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
Morbidity and mortality from masses (GroupA)
Imaging to detect masses when intervention is effective (GroupA) 10NB
SEGA development (GroupA)
mTOR inhibitor treatment (GroupA) 8NB
added MONDO IDs and created scoring groups
2019/10/03
Released (Under revision)
1.1.0
A
LAM development in women
mTOR inhibitor treatment 8NB
Morbidity and mortality from masses
Imaging to detect masses when intervention is effective 10NB
SEGA development
mTOR inhibitor treatment 8NB
Internal system migration related to merging adult and pediatric contexts.
2019/04/04
Released
1.1.0
A
LAM development in women
mTOR inhibitor treatment 8NB
Morbidity and mortality from masses
Imaging to detect masses when intervention is effective 10NB
SEGA development
mTOR inhibitor treatment 8NB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.1
A
LAM development in women
mTOR inhibitor treatment 8NB
Morbidity and mortality from masses
Imaging to detect masses when intervention is effective 10NB
SEGA development
mTOR inhibitor treatment 8NB
Internal system migration related to score text replacement from E to N
2017/11/01
Released
1.0.0
A
LAM development in women
mTOR inhibitor treatment 8EB
Morbidity and mortality from masses
Imaging to detect masses when intervention is effective 10EB
SEGA development
mTOR inhibitor treatment 8EB
¤ Powered by BCM's Genboree.